<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	>
<channel>
	<title>Comments on: Pharmaceutical Companies Will Suffer Under Health Care &#8220;Reform&#8221;</title>
	<atom:link href="http://newledger.com/2009/11/pharmaceutical-companies-will-suffer-under-health-care-reform/feed/" rel="self" type="application/rss+xml" />
	<link>http://newledger.com/2009/11/pharmaceutical-companies-will-suffer-under-health-care-reform/</link>
	<description>The New Ledger on News, Politics, and Market issues of the day. Welcome to the Know.</description>
	<lastBuildDate>Sun, 21 Mar 2010 08:13:33 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: davidzem</title>
		<link>http://newledger.com/2009/11/pharmaceutical-companies-will-suffer-under-health-care-reform/comment-page-1/#comment-1210</link>
		<dc:creator>davidzem</dc:creator>
		<pubDate>Thu, 03 Dec 2009 08:01:23 +0000</pubDate>
		<guid isPermaLink="false">http://newledger.com/?p=21014#comment-1210</guid>
		<description>Friend, everything you say is true but your comment on pharma&#039;s small margin for profit is off. Pharma has one of the largest profit margins in all of business. Their margins have to be high for such a business since there&#039;s such a large risk of losing capitol in failed late-stage trials and overall R&amp;D. But compared to medical device companies and other healthcare related industries, pharma in undoubtedly at the top of the totem pole. While many small start-ups that typically create/research individual molecules will have to close, the majority of pharma will be fine and will pass the costs onto distributors, providers, and ultimately, consumers. More so, with expansion of care, the increase of 30-odd million new customers will probably off set the tax.</description>
		<content:encoded><![CDATA[<p>Friend, everything you say is true but your comment on pharma&#39;s small margin for profit is off. Pharma has one of the largest profit margins in all of business. Their margins have to be high for such a business since there&#39;s such a large risk of losing capitol in failed late-stage trials and overall R&#038;D. But compared to medical device companies and other healthcare related industries, pharma in undoubtedly at the top of the totem pole. While many small start-ups that typically create/research individual molecules will have to close, the majority of pharma will be fine and will pass the costs onto distributors, providers, and ultimately, consumers. More so, with expansion of care, the increase of 30-odd million new customers will probably off set the tax.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
